Literature DB >> 18521229

Concurrent hypofractionated radiotherapy and 5-Fluorouracil for advanced sarcomas of the bone.

C Zambatis1, J Skarlatos, M Koukourakis, L Kosma, A Giatromanolaki, K Beroukas, D Yannakakis.   

Abstract

Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas.Subjects/methods. Four patients with large inoperable bone sarcomas (three chondrosarcomas and one fibrosarcoma) were treated with hypofractionated radiotherapy and concomitant 5-FU bolus injection (300 mg m(-2)) before each fraction of radiotherapy. A radiation fraction of 5 Gy was given twice a week to a normalized total dose (alpha/beta=4 Gy) of 75 Gy.Results. The regimen was well tolerated, the main toxicity being grade I/II diarrhoea in two cases with pelvic irradiation. Treatment interruption for 1 week was necessary in two cases with pelvic disease but not in two patients treated for sarcoma of the extremities. A complete symptomatic relief was obtained in all cases immediately after the third to the fifth fraction and the median duration was 10 months. Computed tomography scan documented a partial response in 2/4 cases.Discussion. Hypofractionated radiotherapy combined with potential lethal damage inhibitors for bone sarcomas requires further investigation.

Entities:  

Year:  1998        PMID: 18521229      PMCID: PMC2395373          DOI: 10.1080/13577149878127

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  13 in total

1.  Osteogenic sarcoma; a study based on 133 patients.

Authors:  S CADE
Journal:  J R Coll Surg Edinb       Date:  1955-12

2.  Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur.

Authors:  M A Simon; M A Aschliman; N Thomas; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1986-12       Impact factor: 5.284

3.  Alpha/beta value and the importance of size of dose per fraction for late complications in the supraglottic larynx.

Authors:  B Maciejewski; J M Taylor; H R Withers
Journal:  Radiother Oncol       Date:  1986-12       Impact factor: 6.280

4.  Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma.

Authors:  A Martinez; D R Goffinet; S S Donaldson; M A Bagshaw; H S Kaplan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-01       Impact factor: 7.038

5.  Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery.

Authors:  L L Hughes; J Luengas; T A Rich; D Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

6.  Radioresponsiveness of human glioma, sarcoma, and breast cancer spheroids depends on tumor differentiation.

Authors:  M Stuschke; V Budach; H Sack
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-10-20       Impact factor: 7.038

7.  Clinical experience with intravenous radiosensitizers in unresectable sarcomas.

Authors:  T J Kinsella; E Glatstein
Journal:  Cancer       Date:  1987-03-01       Impact factor: 6.860

8.  Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival.

Authors:  G Saeter; J Høie; A E Stenwig; A K Johansson; E Hannisdal; O P Solheim
Journal:  Cancer       Date:  1995-03-01       Impact factor: 6.860

9.  Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning.

Authors:  E B Hug; M M Fitzek; N J Liebsch; J E Munzenrider
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-02-01       Impact factor: 7.038

10.  Chondrosarcoma: a clinicopathologic and statistical analysis.

Authors:  D J Pritchard; R J Lunke; W F Taylor; D C Dahlin; B E Medley
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.